Advanced searches left 3/3

Carcinoma Pembrolizumab - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 January 2023

* If you want to update the article please login/register

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.

Background/aim We wanted to establish the relationship between body mass index and clinical results of pembrolizumab therapy for advanced urothelial cancer. Patients with advanced UC who received pesografb after chemotherapy between March 2018 and December 2021 retrospectively reviewed the patient files from patients with pesotropholizumab after chemotherapy between March 2018 and December 2021. Patients were divided into BMI into the non-overweight group and the overweight group according to BMI. Although the objective response rate in the overweight group was higher in the overweight group than in the non-overweight group, the difference was not significant. The difference was not significant in 15 and 5 patients in the non-overweight group, respectively, and in 8 and 2 patients in the overweight group, respectively. Conclusion BMI was connected with oncologic results in patients with advanced UC who received pemozizumab, but not with the emergence of irAEs.

Source link: https://europepmc.org/article/MED/36585166


Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response

Many solid organ and hematologic malignancies are now being treated with immunoglobe checkpoint inhibitors. In the literature, dermatological disorders connected with programmed cell death protein-1 and programmed death ligand-1 therapy have been common. Lichen planus is an inflammatory disease that is frequently present in areas of the skin and oral mucous membrane lining. Cutaneous toxicities are among the most common adverse events with this class of drugs. We present a case of lichen planus in a 66-year-old male patient receiving pesozumab for stage IV non-small cell lung cancer. Pembrolizumab is a drug that aids immune cells in killing cancer cells by binding to the PD-1 protein. This case illustrates the potential cutaneous side effects of pesezumab in a patient with peeolizumab, as well as the fact that it can act as a 'clinical biomarker'' and show therapeutic effectiveness of the therapy.

Source link: https://europepmc.org/article/MED/PMC9747249


The Unique Case of Lumbar Dural Metastasis From Cervical Carcinoma on Pembrolizumab.

Lumbar metastasis is a rare occurrence of cervical carcinoma that may present as lower extremities signs. A 52-year-old female with metastatic cervical cancer on pemolizumab has been suffering with lower back pain, progressive bilateral lower extremities, and elasticized limbs. The L4-L5 fracture was seen on magnetic resonance imaging, which confirmed metastasis and contrast-enhancing nearby dura and nerve roots. In this case, the peculiar clinical situation of lumbar dural metastasis from cervical cancer on peso is investigated.

Source link: https://europepmc.org/article/MED/36540313


Bilateral choroidal effusions and angle closure in the setting of systemic capillary leak syndrome from HLA-directed vaccine and pembrolizumab therapy for squamous cell carcinoma.

Purpose Immunotherapy has emerged as a vital adjunct to oncology therapy efforts in recent years. The most well-documented side effects of immune checkpoint inhibitors in ophthalmology include uveitis, macular edema, and dry eye syndrome. In the case of systemic choroidal effusions and secondary angle narrowing, an HLA-directed vaccine and an ICI, pemo cell carcinoma of the lung, authoritarian squamous cell carcinoma of the lung, this manuscript explores unusual case of bilateral choroidal effusions and secondary angle narrowing. Observations After receiving an HLA-directed vaccine in combination with pemmea, a 67-year-old male with a history of stage IV SCC of the lung status-post pneumonectomy presented to the emergency department due to functional decline, anasarca, and dyspnea after being given an HLA-directed vaccine in conjunction with pemnea. Conclusions and importance Choroidal effusions and secondary angle closure can be important issues of SCLS in the context of ICIs.

Source link: https://europepmc.org/article/MED/36578801


Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.

Background and purpose Pembrolizumab has now become a benchmark of care for metastatic urothelial carcinoma, but individual results are not consistent. The median radiation dose and fraction were 30 Gy and 10 fractions, respectively, in 71 patients for whom palliative radiation was performed. Patients with concurrent palliative radiation with pembrolizumab were much longer in patients with palliative radiation before pembrolizumab than in those without palliative radiation throughout the follow-up. Patients treated with concurrent palliative radiation with pepliative drug compared to patients in the two matched cohorts found that they were still matched after the propensity-score matching by putative confounding factors, the longer OS in patients treated with concurrent palliative radiation with pembrolizumab was also observed. Conclusions Our findings reveal that the simultaneous administration of palliative radiation with penetolizumab has a positive effect on OS in platinum-refractory mUC patients.

Source link: https://europepmc.org/article/MED/36545361


Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.

Background of Pembrolizumab for esophageal squamous cell carcinoma patients with a programmed death ligand-1 combined positive score u2265 10. However, despite the increased survival rate in these patients as a result of pembrolizumab, pesinolizumab's high cost may have an effect on its antitumor response. Based on the KEYNOTE-181 trial, this research aimed to determine whether pembrolizumab cost-effectiveness compared to chemotherapy as second-line therapies for esophageal carcinoma. Methods The Markov model was built using TreeAge 2021 and three related organizations: all intent-to-treat patients, patients with ESCC, and patients with a PD-L1 CPS u226510 u226510. Conclusions The determination of perogolizumab as a cost-effective second-line therapy for EC in the United States is influenced by the histologic type and PD-L1 expression.

Source link: https://europepmc.org/article/MED/36568792


Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report.

There have been no reports about sebaceous carcinoma primary lung cancer, for which optimal therapy has yet to be established. The morphological characteristics of the iliac bone biopsy pathology and immunostaining results revealed sebaceous gland differentiation, according to sebaceous gland differentiation. Using the Oncomine Dx target test, we found protein kinase B mutations. Both RT and pembrolizumab are potential treatment options for certain rare primary sebaceous carcinomas of the lungs. Tumor reduction may have been influenced by a synergistic effect of RT and subsequent administration of immune checkpoint inhibitors.

Source link: https://europepmc.org/article/MED/36484334


Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.

Penetroplasty urothelial carcinoma patients are often prescribed with a monoclonal antibody targeting programmed cell death. Although the survival benefit of pembrolizumab was demonstrated in the well-planned phase III trial, these results only represent a sample of patients due to strictly defined eligibility criteria. This review summarizes the latest available research on pemolizumab in platinum-refractory UCs and addresses the clinical risk factors and efficacy for trial-ineligible patients.

Source link: https://europepmc.org/article/MED/36482843


Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Background Immune checkpoint inhibitors are a common therapy in metastatic urothelial carcinoma. Patients and methods In KEYNOTE-045, patients with platinum-containing chemotherapy who progressed on platinum-containing chemotherapy were randomly selected 1:1 to receive pecetaxel, docetaxel, or vinflunine, according to the investigator's preference. Pemolizumab was first-line pembrolizumab in KEYNOTE-052, cisplatin-ineligible patients with metastatic UC. OS rates in pesozumab and 10. 1% for chemotherapy were 17. 7% at 48 months, respectively; PFS rates were 9. 5% and 2. 7%, respectively. The median duration of response was 29. 7 months for pesolizumab and 4. 4 months for chemotherapy; 36-month DOR rates were 44. 4% and 28. 3% respectively; Both studies' pessimist adverse events for petolizumab were either grade 1 or 2 and manageable, which is consistent with previous studies. Conclusion With no new safety data in patients with platinum-resistant metastatic UC and as first-line therapy in cisplatin-ineligible patients, peplatin-ineligible patients, peglizumab monotherapy continued to show long-term success, with no new safety signals in patients with pesplatin-ineligible patients.

Source link: https://europepmc.org/article/MED/36494006

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions